Experience of Treating COVID-19 With Remdesivir and Convalescent Plasma in a Resource-Limited Setting: A Prospective, Observational Study
Janak Koirala,Pradip Gyanwali,Robert B Gerzoff,Saroj Bhattarai,Bipin Nepal,Rekha Manandhar,Runa Jha,Sanjib Sharma,Yuba Raj Sharma,Anup Bastola,Holly Murphy,Subhash Acharya,Prabhat Adhikari,Manita Rajkarnikari,Karishma M Vaidya,Chhabi L Panthi,Bihungum Bista,Grishma Giri,Shambhu Aryal,Suman Pant,Akritee Pokharel,Shristi Karki,Sangita Basnet,Bhagawan Koirala,Meghnath Dhimal,Nepal COVID-19 Clinical Study Collaborators,Roshan Kumar Jha,Anil Shrestha,Ashesh Dhungana,Shreejana Shrestha,Sarita Pandey,Sangita Shakya,Philip S Ranjit,Sunil Dhungel,Devendra Bhattarai,Sumitra Gautam,Pramod Poudel,Kalyan Sapkota,Khagendra J Shah,Rajesh K Mandal,Rajan Pandey,Sumit Prajapati,Arif Hussain,Shakuntala Gupta,Roshan Chhetri,Krishna Pokharel,Kala Thapa,Shital Adhikari,Gopendra P Deo,Basanta Gauli,Pukar Ghimire,Bishnu Regmi,Ram B Gurung,Rajeev Shrestha,Dipesh Tamrakar,Sushil Khanal,Upasana Acharya,Suhail Sapkota,Reema Shrestha,Milesh J Sijapati,Smriti Koirala,Suraj Bajracharya,Deepak Sigdel,Den P Acharya,Sudarshan Chhetri,Prashanta Acharya,Hari P Panthi,Achyut R Karki,Ram K Singh,Uday N Singh,Rakesh Tiwari,Asraf Hussain,Rupesh Shah,Parwez A Ansari,Diptesh Aryal,Sanjit K Shrestha,Kanchan Koirala,Kiran Kumar Kc,Bidur P Acharya,Shyam Bk,Sumit Pandey,Suraj K Gupta,Deepa Shakya,Yunima Sapkota,Anju Adhikari,Bishwanath Koirala,Bipin Karki,Yuba R Sharma,Bimal K Pandey,Buddhi S Lamichhane,Sanjay Shrestha,Sher B Kamar,Ashok Chaudhary,Jagdish Joshi,Kunjang Sherpa,Reeju Manandhar,Chiranjibi Pant,Rinku Joshi,Bimal S Chalise,Santa K Das,Pramesh S Shrestha
DOI: https://doi.org/10.1093/ofid/ofab391
2021-08-21
Abstract:Background: Convalescent plasma therapy (CPT) and remdesivir (REM) have been approved for investigational use to treat coronavirus disease 2019 (COVID-19) in Nepal. Methods: In this prospective, multicentered study, we evaluated the safety and outcomes of treatment with CPT and/or REM in 1315 hospitalized COVID-19 patients over 18 years in 31 hospitals across Nepal. REM was administered to patients with moderate, severe, or life-threatening infection. CPT was administered to patients with severe to life-threatening infections who were at high risk for progression or clinical worsening despite REM. Clinical findings and outcomes were recorded until discharge or death. Results: Patients were classified as having moderate (24.2%), severe (64%), or life-threatening (11.7%) COVID-19 infection. The majority of CPT and CPT + REM recipients had severe to life-threatening infections (CPT 98.3%; CPT + REM 92.1%) and were admitted to the intensive care unit (ICU; CPT 91.8%; CPT + REM 94.6%) compared with those who received REM alone (73.3% and 57.5%, respectively). Of 1083 patients with reported outcomes, 78.4% were discharged and 21.6% died. The discharge rate was 84% for REM (n = 910), 39% for CPT (n = 59), and 54.4% for CPT + REM (n = 114) recipients. In a logistic model comparing death vs discharge and adjusted for age, gender, steroid use, and severity, the predicted margin for discharge was higher for recipients of remdesivir alone (0.82; 95% CI, 0.79-0.84) compared with CPT (0.58; 95% CI, 0.47-0.70) and CPT + REM (0.67; 95% CI, 0.60-0.74) recipients. Adverse events of remdesivir and CPT were reported in <5% of patients. Conclusions: This study demonstrates a safe rollout of CPT and REM in a resource-limited setting. Remdesivir recipients had less severe infection and better outcomes.ClinicalTrials.gov identifier. NCT04570982.